Louise Raunkilde
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Louise Raunkilde has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Lars Henrik Jensen
Department of Oncology, University Hospital of Southern Denmark, Vejle Hospital, Vejle, Denmark
7 shared publications - Torben Hansen
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen N, Denmark
4 shared publications - Caroline Brenner Thomsen
Danish Colorectal Cancer Center South, Vejle Hospital, Vejle, Denmark
3 shared publications - Rikke Fredslund Andersen
Department of Biochemistry and Immunology Vejle Hospital, University Hospital of Southern Denmark Denmark
3 shared publications - Ahmed Hussein Zedan
Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, 7100 Vejle, Denmark
2 shared publications Caroline Brenner Thomsen
Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Beriderbakken 4, 7100, Vejle, Denmark; Danish Colorectal Cancer Center South, Vejle Hospital, Beriderbakken 4, 7100, Vejle, Denmark
2 shared publications
Latest Publications
- Open Access
- 19 October 2025
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 1420-1429
Natural killer cell activity in prostate cancer patients treated with curative radiotherapy with or without androgen deprivation therapy: an observational study
Background and purpose: Natural killer (NK) cells play an important role in defense against cancer. Low NK cell activity (NKA) has been linked to prostate cancer (PCa) detection, and effective NKA may be associated with better prognosis in metastatic PCa. Radiotherapy (RT) could affect the immune response, but data on NKA in patients with PCa receiving RT ± androgen deprivation therapy (ADT) remain limited. Hence, this study investigated NKA in such patients. Patient/material and methods: Peripheral blood from 150 patients with PCa receiving curatively intended RT was collected into NK Vue® tubes prior to RT (baseline, BL), after end of RT (EOT), and during follow-up. Patients received 0- (n = 15), 6- (n = 23), or 36-months of ADT (n = 112), starting 3 months before RT. Interferon-γ was a surrogate marker for NKA in NK Vue® tubes. Data were analyzed using descriptive statistics. Results: Baseline characteristics were similar between patients with normal (≥ 250 pg/mL) (n = 46) and low (< 250 pg/mL) (n = 104) NKA; however, smoking was more prevalent in the low NKA group (28% vs. 11%). The distribution of NKA levels differed between groups and time points, notably showing a decreased interquartile range (IQR) for all groups at EOT (BL median 832 pg/mL, IQR 2901; EOT median 312 pg/mL, IQR 708). NKA fluctuated during follow-up and did not mirror prostate-specific antigen dynamics. Interpretation: Patients with localized PCa treated with RT ± ADT displayed marked variation in NKA, including treatment-related dynamics. The overall complexity and heterogeneity of NKA raise questions about its clinical utility as a biomarker in this setting.
- 19 October 2025
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 1420-1429
Open AccessNatural killer cell activity in prostate cancer patients treated with curative radiotherapy with or without androgen deprivation therapy: an observational study
Background and purpose: Natural killer (NK) cells play an important role in defense against cancer. Low NK cell activity (NKA) has been linked to prostate cancer (PCa) detection, and effective NKA may be associated with better prognosis in metastatic PCa. Radiotherapy (RT) could affect the immune response, but data on NKA in patients with PCa receiving RT ± androgen deprivation therapy (ADT) remain limited. Hence, this study investigated NKA in such patients. Patient/material and methods: Peripheral blood from 150 patients with PCa receiving curatively intended RT was collected into NK Vue® tubes prior to RT (baseline, BL), after end of RT (EOT), and during follow-up. Patients received 0- (n = 15), 6- (n = 23), or 36-months of ADT (n = 112), starting 3 months before RT. Interferon-γ was a surrogate marker for NKA in NK Vue® tubes. Data were analyzed using descriptive statistics. Results: Baseline characteristics were similar between patients with normal (≥ 250 pg/mL) (n = 46) and low (< 250 pg/mL) (n = 104) NKA; however, smoking was more prevalent in the low NKA group (28% vs. 11%). The distribution of NKA levels differed between groups and time points, notably showing a decreased interquartile range (IQR) for all groups at EOT (BL median 832 pg/mL, IQR 2901; EOT median 312 pg/mL, IQR 708). NKA fluctuated during follow-up and did not mirror prostate-specific antigen dynamics. Interpretation: Patients with localized PCa treated with RT ± ADT displayed marked variation in NKA, including treatment-related dynamics. The overall complexity and heterogeneity of NKA raise questions about its clinical utility as a biomarker in this setting.
- Open Access
- 6 January 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (5) , 109586
A prospective study of methylated ctDNA in patients undergoing treatment for liver metastases from colorectal cancer
- 6 January 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (5) , 109586
Open AccessA prospective study of methylated ctDNA in patients undergoing treatment for liver metastases from colorectal cancer
- Open Access
Development and clinical application of a methylated ctDNA assay in the preoperative risk classification of resectable colon cancer
Background: Pathological lymph node involvement (pN+) is an indicator of poor prognosis in localized colon cancer. Currently, the preoperative risk classification fails to accurately identify pN+, which could be instrumental in the selection of patients for neoadjuvant chemotherapy (NAC). This study aimed to develop an assay for preoperative methylated circulating tumor DNA (meth-ctDNA) as a predictive marker of pN+ and as a biomarker for initiating NAC in patients with localized colon cancer. Materials and methods: 203 patients operated for colon cancer stage I-III at Vejle Hospital were randomly assigned (1:1) to a discovery and a validation cohort. A multiplex assay of a tumor-specific (NPY) and two organ-specific (GAL3ST3, KANK1) meth-ctDNAs was designed and methylation analysis was performed using droplet digital PCR. The ability of preoperative meth-ctDNA to predict pN+ was assessed using receiver operating characteristics (ROC) analysis. Results: ROC analyses of meth-ctDNA (negative/positive) to predict pN+ had an area under the curve of 52% and 57% in the discovery and validation cohort, respectively. Survival analysis in the validation cohort confirmed a higher rate of 48 months disease-free survival in meth-ctDNA negative compared to positive patients (HR=2.31, 95% CI 1.01-5.2). The difference also applied to 4-year overall survival (HR=3.62, 95% CI 1.15-11.4). In a multivariate analysis, meth-ctDNA remained the strongest prognostic factor of DFS (HR 2.46, 95% CI 1.03-5.88) and OS (HR 4.54, 95% CI 1.32-15.6) in relation to clinical T- or N-category, gender and age. Conclusion: The preoperative meth-ctDNA multiplex assay did not predict pN+. The findings suggest meth-ctDNA as a more powerful marker than N-category in identifying high-risk patients who would potentially benefit from NAC.
Open AccessDevelopment and clinical application of a methylated ctDNA assay in the preoperative risk classification of resectable colon cancer
Background: Pathological lymph node involvement (pN+) is an indicator of poor prognosis in localized colon cancer. Currently, the preoperative risk classification fails to accurately identify pN+, which could be instrumental in the selection of patients for neoadjuvant chemotherapy (NAC). This study aimed to develop an assay for preoperative methylated circulating tumor DNA (meth-ctDNA) as a predictive marker of pN+ and as a biomarker for initiating NAC in patients with localized colon cancer. Materials and methods: 203 patients operated for colon cancer stage I-III at Vejle Hospital were randomly assigned (1:1) to a discovery and a validation cohort. A multiplex assay of a tumor-specific (NPY) and two organ-specific (GAL3ST3, KANK1) meth-ctDNAs was designed and methylation analysis was performed using droplet digital PCR. The ability of preoperative meth-ctDNA to predict pN+ was assessed using receiver operating characteristics (ROC) analysis. Results: ROC analyses of meth-ctDNA (negative/positive) to predict pN+ had an area under the curve of 52% and 57% in the discovery and validation cohort, respectively. Survival analysis in the validation cohort confirmed a higher rate of 48 months disease-free survival in meth-ctDNA negative compared to positive patients (HR=2.31, 95% CI 1.01-5.2). The difference also applied to 4-year overall survival (HR=3.62, 95% CI 1.15-11.4). In a multivariate analysis, meth-ctDNA remained the strongest prognostic factor of DFS (HR 2.46, 95% CI 1.03-5.88) and OS (HR 4.54, 95% CI 1.32-15.6) in relation to clinical T- or N-category, gender and age. Conclusion: The preoperative meth-ctDNA multiplex assay did not predict pN+. The findings suggest meth-ctDNA as a more powerful marker than N-category in identifying high-risk patients who would potentially benefit from NAC.
- 30 August 2023
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 62 (9) , 1066-1075
Delta tocotrienol as a supplement to FOLFOXIRI in first-line treatment of metastatic colorectal cancer. A randomized, double-blind, placebo-controlled phase II study
Triplet chemotherapy might be more effective than doublet chemotherapy in metastatic colorectal cancer (mCRC), but it may also be marked by increased toxicity. To investigate whether δ-tocotrienol, a vitamin E analogue, with possible neuroprotective and anti-inflammatory effects, reduces the toxicity of triplet chemotherapy, we conducted a randomized, double-blind, placebo-controlled trial in mCRC patients receiving first-line 5-fluorouracil, oxaliplatin and irinotecan (FOLFOXIRI). Seventy patients with mCRC were randomly assigned (1:1) to receive FOLFOXIRI plus either δ-tocotrienol or placebo at the Department of Oncology, Vejle Hospital, Denmark. Eligibility criteria were adenocarcinoma in the colon or rectum, age 18-75 years and ECOG performance status 0-1. FOLFOXIRI was given in eight cycles followed by four cycles of 5-fluorouracil. δ-tocotrienol 300 mg or placebo × 3 daily was added during chemotherapy and for a maximum of two years. The primary endpoint was time to hospitalization or death during treatment with chemotherapy. Median time to first hospitalization or death was 3.7 months in the placebo group (95% CI 1.93-not reached (NR)), and was NR in the δ-tocotrienol group (95% CI 1.87-NR) with a hazard ratio of 0.70 (95% CI 0.36-1.36). Grade 3-4 toxicities were uncommon in both groups, except for neutropenia, which occurred in 19 patients (58%) in the placebo group and 17 patients (50%) in the δ-tocotrienol group. There were no grade 3 or 4 peripheral sensory neuropathy. In the placebo group, 24 patients (71%) had oxaliplatin dose reductions compared to 17 patients (47%) in the δ-tocotrienol group (p = 0.047). The addition of δ-tocotrienol to FOLFOXIRI did not statistically significant prolong the time to first hospitalization or death compared to FOLFOXIRI plus placebo. Toxicity was manageable and not statistically different. There was a statistically significant difference in dose reductions of oxaliplatin pointing to a possible neuroprotective effect of δ-tocotrienol.
- 30 August 2023
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 62 (9) , 1066-1075
Delta tocotrienol as a supplement to FOLFOXIRI in first-line treatment of metastatic colorectal cancer. A randomized, double-blind, placebo-controlled phase II study
Triplet chemotherapy might be more effective than doublet chemotherapy in metastatic colorectal cancer (mCRC), but it may also be marked by increased toxicity. To investigate whether δ-tocotrienol, a vitamin E analogue, with possible neuroprotective and anti-inflammatory effects, reduces the toxicity of triplet chemotherapy, we conducted a randomized, double-blind, placebo-controlled trial in mCRC patients receiving first-line 5-fluorouracil, oxaliplatin and irinotecan (FOLFOXIRI). Seventy patients with mCRC were randomly assigned (1:1) to receive FOLFOXIRI plus either δ-tocotrienol or placebo at the Department of Oncology, Vejle Hospital, Denmark. Eligibility criteria were adenocarcinoma in the colon or rectum, age 18-75 years and ECOG performance status 0-1. FOLFOXIRI was given in eight cycles followed by four cycles of 5-fluorouracil. δ-tocotrienol 300 mg or placebo × 3 daily was added during chemotherapy and for a maximum of two years. The primary endpoint was time to hospitalization or death during treatment with chemotherapy. Median time to first hospitalization or death was 3.7 months in the placebo group (95% CI 1.93-not reached (NR)), and was NR in the δ-tocotrienol group (95% CI 1.87-NR) with a hazard ratio of 0.70 (95% CI 0.36-1.36). Grade 3-4 toxicities were uncommon in both groups, except for neutropenia, which occurred in 19 patients (58%) in the placebo group and 17 patients (50%) in the δ-tocotrienol group. There were no grade 3 or 4 peripheral sensory neuropathy. In the placebo group, 24 patients (71%) had oxaliplatin dose reductions compared to 17 patients (47%) in the δ-tocotrienol group (p = 0.047). The addition of δ-tocotrienol to FOLFOXIRI did not statistically significant prolong the time to first hospitalization or death compared to FOLFOXIRI plus placebo. Toxicity was manageable and not statistically different. There was a statistically significant difference in dose reductions of oxaliplatin pointing to a possible neuroprotective effect of δ-tocotrienol.
- Open Access
The Clinical Impact of Methylated Homeobox A9 ctDNA in Patients with Non-Resectable Biliary Tract Cancer Treated with Erlotinib and Bevacizumab
Methylated homeobox A9 (meth-HOXA9) is tumor specific and has been suggested as a prognostic biomarker in several types of cancer. ctDNA measured as meth-HOXA9 may be a valuable biomarker in the decision-making process about last-line treatment of biliary tract cancer (BTC). The aim of the study was to investigate the clinical impact of meth-HOXA9 in plasma from patients receiving erlotinib and bevacizumab for late-stage BTC and to investigate the treatment effect and adverse events. Droplet digital PCR was applied to detect meth-HOXA9 in 39 patients. Response rates were registered according to RECIST (1.1) and adverse events according to Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE (4.0)). Endpoints were progression-free survival (PFS), overall survival (OS), response rate, and toxicity. A significant difference in PFS and OS between patients with increasing and non-increasing meth-HOXA9 was detected after one treatment cycle, hazard ratio (HR) 12.4 (p < 0.0001) and HR 2.75 (p = 0.04), respectively. The most common adverse events of erlotinib were fatigue, pain, and rash, and those of bevacizumab were bleeding and wounds. This study found meth-HOXA9 to be negatively associated with survival in patients with late-stage BTC. Hence, meth-HOXA9 may guide early discontinuation of ineffective treatment.
Open AccessThe Clinical Impact of Methylated Homeobox A9 ctDNA in Patients with Non-Resectable Biliary Tract Cancer Treated with Erlotinib and Bevacizumab
Methylated homeobox A9 (meth-HOXA9) is tumor specific and has been suggested as a prognostic biomarker in several types of cancer. ctDNA measured as meth-HOXA9 may be a valuable biomarker in the decision-making process about last-line treatment of biliary tract cancer (BTC). The aim of the study was to investigate the clinical impact of meth-HOXA9 in plasma from patients receiving erlotinib and bevacizumab for late-stage BTC and to investigate the treatment effect and adverse events. Droplet digital PCR was applied to detect meth-HOXA9 in 39 patients. Response rates were registered according to RECIST (1.1) and adverse events according to Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE (4.0)). Endpoints were progression-free survival (PFS), overall survival (OS), response rate, and toxicity. A significant difference in PFS and OS between patients with increasing and non-increasing meth-HOXA9 was detected after one treatment cycle, hazard ratio (HR) 12.4 (p < 0.0001) and HR 2.75 (p = 0.04), respectively. The most common adverse events of erlotinib were fatigue, pain, and rash, and those of bevacizumab were bleeding and wounds. This study found meth-HOXA9 to be negatively associated with survival in patients with late-stage BTC. Hence, meth-HOXA9 may guide early discontinuation of ineffective treatment.
- Open Access
NPY Gene Methylation in Circulating Tumor DNA as an Early Biomarker for Treatment Effect in Metastatic Colorectal Cancer
Despite several limitations, the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) are still the gold standard in response evaluation of metastatic colorectal cancer (mCRC). The aim of the present study was to investigate hypermethylated neuropeptide Y circulating tumor DNA (meth-NPY) as an early biomarker for treatment effect and monitoring in 70 mCRC patients receiving first-line treatment in the FOLFOXIRI-Toco trial. Meth-NPY was analyzed using droplet digital PCR, and the response rate was defined as the fraction of patients converting from a baseline detectable level to an undetectable level after the first treatment cycle (responders). A significant increase in meth-NPY was defined as a value with no overlap between the 95% CI of the current and preceding measurement. Progression-free survival (PFS) was significantly longer in meth-NPY responders compared to non-responders, 10.1 and 7.6 months, respectively (p = 0.02, HR = 0.43). Patients with response according to RECIST 1.1 had a PFS of 10.1 compared to 7.3 months for non-responders (p = 0.17, HR = 0.65). A significant increase in meth-NPY was found with a median of 49 days before radiological progression. In conclusion, early meth-NPY response proved superior to response according to RECIST 1.1 with respect to predicting improved PFS. Meth-NPY is an early indicator of progression, allowing treatment reorientation at an earlier timepoint.
Open AccessNPY Gene Methylation in Circulating Tumor DNA as an Early Biomarker for Treatment Effect in Metastatic Colorectal Cancer
Despite several limitations, the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) are still the gold standard in response evaluation of metastatic colorectal cancer (mCRC). The aim of the present study was to investigate hypermethylated neuropeptide Y circulating tumor DNA (meth-NPY) as an early biomarker for treatment effect and monitoring in 70 mCRC patients receiving first-line treatment in the FOLFOXIRI-Toco trial. Meth-NPY was analyzed using droplet digital PCR, and the response rate was defined as the fraction of patients converting from a baseline detectable level to an undetectable level after the first treatment cycle (responders). A significant increase in meth-NPY was defined as a value with no overlap between the 95% CI of the current and preceding measurement. Progression-free survival (PFS) was significantly longer in meth-NPY responders compared to non-responders, 10.1 and 7.6 months, respectively (p = 0.02, HR = 0.43). Patients with response according to RECIST 1.1 had a PFS of 10.1 compared to 7.3 months for non-responders (p = 0.17, HR = 0.65). A significant increase in meth-NPY was found with a median of 49 days before radiological progression. In conclusion, early meth-NPY response proved superior to response according to RECIST 1.1 with respect to predicting improved PFS. Meth-NPY is an early indicator of progression, allowing treatment reorientation at an earlier timepoint.
- Open Access
- 11 January 2022
- Published by Springer Nature in Research Square
Delta Tocotrienol as a Supplement to FOLFOXIRI in First Line Treatment of Metastatic Colorectal Cancer. A Randomized, Double-blind, Placebo-controlled Phase II Study
Purpose Triplet chemotherapy might be more effective than doublet chemotherapy in metastatic colorectal cancer (mCRC), but it may also be marked by increased toxicity. To investigate whether δ-tocotrienol, a vitamin E analogue, with its possible neuroprotective and anti-inflammatory effects reduces the toxicity of triplet chemotherapy, we conducted a randomized, double-blind, placebo controlled trial in mCRC patients receiving first line 5-fluorouracil, oxaliplatin and irinotecan (FOLFOXIRI).Methods We randomly assigned 70 mCRC patients to FOLFOXIRI plus δ-tocotrienol or FOLFOXIRI plus placebo. FOLFOXIRI was given in eight cycles followed by four cycles of 5-fluorouracil. δ-tocotrienol 300 mg or placebo x 3 daily was added during chemotherapy and for a maximum of two years. The primary endpoint was time to hospitalization or death during treatment with chemotherapy.Results Median time to first hospitalization or death was 3.7 months in the placebo group (95% CI 1.93-not reached (NR)), and NR in the δ-tocotrienol group (95% CI 1.87-NR) with a hazard ratio (HR) of 0.70 (95% CI 0.36-1.36, p=0.29)). In the placebo group 24 patients (71%) had oxaliplatin dose reductions compared to 17 patients (47%) in the δ-tocotrienol group (p=0.047).Conclusion The addition of δ-tocotrienol to FOLFOXIRI did not significantly prolong the time to first hospitalization or death compared to FOLFOXIRI plus placebo. Toxicity was manageable and not statistically different between the two groups. There was a statistically significant difference in dose reductions of oxaliplatin pointing to a possible neuroprotective effect of δ-tocotrienol.Clinicaltrials.gov identifier NCT02705300. Date of registration March 10, 2016.
- 11 January 2022
- Published by Springer Nature in Research Square
Open AccessDelta Tocotrienol as a Supplement to FOLFOXIRI in First Line Treatment of Metastatic Colorectal Cancer. A Randomized, Double-blind, Placebo-controlled Phase II Study
Purpose Triplet chemotherapy might be more effective than doublet chemotherapy in metastatic colorectal cancer (mCRC), but it may also be marked by increased toxicity. To investigate whether δ-tocotrienol, a vitamin E analogue, with its possible neuroprotective and anti-inflammatory effects reduces the toxicity of triplet chemotherapy, we conducted a randomized, double-blind, placebo controlled trial in mCRC patients receiving first line 5-fluorouracil, oxaliplatin and irinotecan (FOLFOXIRI).Methods We randomly assigned 70 mCRC patients to FOLFOXIRI plus δ-tocotrienol or FOLFOXIRI plus placebo. FOLFOXIRI was given in eight cycles followed by four cycles of 5-fluorouracil. δ-tocotrienol 300 mg or placebo x 3 daily was added during chemotherapy and for a maximum of two years. The primary endpoint was time to hospitalization or death during treatment with chemotherapy.Results Median time to first hospitalization or death was 3.7 months in the placebo group (95% CI 1.93-not reached (NR)), and NR in the δ-tocotrienol group (95% CI 1.87-NR) with a hazard ratio (HR) of 0.70 (95% CI 0.36-1.36, p=0.29)). In the placebo group 24 patients (71%) had oxaliplatin dose reductions compared to 17 patients (47%) in the δ-tocotrienol group (p=0.047).Conclusion The addition of δ-tocotrienol to FOLFOXIRI did not significantly prolong the time to first hospitalization or death compared to FOLFOXIRI plus placebo. Toxicity was manageable and not statistically different between the two groups. There was a statistically significant difference in dose reductions of oxaliplatin pointing to a possible neuroprotective effect of δ-tocotrienol.Clinicaltrials.gov identifier NCT02705300. Date of registration March 10, 2016.
- Open Access
- 1 July 2019
- Published by Elsevier in Translational Oncology
- Vol. 12 (7) , 968-972
Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer
- 1 July 2019
- Published by Elsevier in Translational Oncology
- Vol. 12 (7) , 968-972
Open AccessCorrelation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer
- 2 October 2017
- Vol. 179 (40)
[Immunotherapy is cancer treatment with a novel side-effect profile].
Within the last few years we have treated still more types of cancer with immune checkpoint inhibitors - anti-cytotoxic T-lymphocyte-associated-4 antibodies and anti-program-med cell death 1/anti-programmed cell death ligand 1 antibodies. A unique set of side effects called immune related adverse events irAEs may occur during treatment. Although severe irAEs remain rare they can become life-threatening. Early detection of irAEs and initiation of relevant treatment are therefore crucial to reduce the risk of long-term seque-lae. We provide a detailed overview of irAEs and recommendations for treatment according to established guidelines.
- 2 October 2017
- Vol. 179 (40)
[Immunotherapy is cancer treatment with a novel side-effect profile].
Within the last few years we have treated still more types of cancer with immune checkpoint inhibitors - anti-cytotoxic T-lymphocyte-associated-4 antibodies and anti-program-med cell death 1/anti-programmed cell death ligand 1 antibodies. A unique set of side effects called immune related adverse events irAEs may occur during treatment. Although severe irAEs remain rare they can become life-threatening. Early detection of irAEs and initiation of relevant treatment are therefore crucial to reduce the risk of long-term seque-lae. We provide a detailed overview of irAEs and recommendations for treatment according to established guidelines.